NASDAQ$MNKD
MannKind Corp · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
MannKind reported first quarter 2024 financial results, showing substantial revenue growth and advancements in clinical development.
MannKind Corporation reported a strong first quarter in 2024, marked by a 63% increase in total revenues to $66 million and a net income of $11 million. The company also highlighted clinical development progress, including FDA Fast Track designation and IND clearance for MNKD-101.
- Total revenues reached $66 million, a 63% increase compared to Q1 2023.
- Net income was reported at $11 million, with a non-GAAP net income of $15 million.
- Cash and cash equivalents totaled $304 million as of March 31, 2024.
- FDA Fast Track designation and IND clearance were received for MNKD-101.
Headline financials
Revenue & EPS history
MannKind · Revenue · Quarterly
$66.3M
Revenue by segment
MannKind · $31M total across 3 segments · Q3 2023
- Afrezza$13.5M—43.4%
- Collaborations and services$13.1M—42.2%
- V-Go$4.45M—14.3%
Forward guidance
MannKind is progressing with clinical trials and expects key data readouts and FDA submissions in the coming quarters. The company anticipates continued growth and innovation in its product pipeline.
Tailwinds
- Patient enrollment and randomization completed in 1Q 2024 for Afrezza INHALE-1 (pediatric phase 3 clinical trial)
- Last participant completed randomized treatment phase in 1Q 2024 for Afrezza INHALE-3
- FDA Fast Track designation received for MNKD-101
- FDA clearance of Investigational New Drug Application (IND) for MNKD-101
- FDA clearance to proceed to Phase 1 clinical trial for MNKD-201
Headwinds
- Risks associated with manufacturing and supply
- Risks associated with developing product candidates
- Risks and uncertainties related to unforeseen delays that may impact the timing of progressing clinical trials and reporting data
- Risks associated with safety and other complications of our products and product candidates
- Risks associated with the regulatory review process
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-0.4%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+1.5%
Avg return
30 days after
39%
25 / 64 earnings
Positive
+44.9%
Q3 2016
Best reaction
-28.5%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +24.5% | +17.5% | +18.5% | |
| Q4 2025 | -6.9% | -16.3% | -34.9% | |
| Q3 2025 | +10.6% | -1.1% | +3.6% | |
| Q1 2025 | -4.5% | -2.7% | -9.7% | |
| Q4 2024 | -4.4% | -5.9% | -8.0% | |
| Q3 2024 | -1.2% | -4.8% | -8.6% | |
| Q2 2024 | -1.5% | -1.5% | +12.5% | |
| Q1 2024 | -3.6% | -1.3% | +4.5% | |
| Q4 2023 | +9.5% | +25.7% | +26.5% | |
| Q3 2023 | -0.8% | -6.8% | -0.3% | |
| Q2 2023 | +15.5% | +11.2% | -3.8% | |
| Q1 2023 | +13.4% | +9.0% | +6.2% | |
| Q4 2022 | +4.2% | +1.7% | -23.1% | |
| Q3 2022 | +6.3% | +20.7% | +32.8% | |
| Q2 2022 | -1.4% | -4.6% | -9.0% | |
| Q1 2022 | -8.7% | -8.7% | +42.7% | |
| Q4 2021 | -25.7% | -24.9% | -5.2% | |
| Q3 2021 | -0.6% | +3.1% | -14.3% | |
| Q2 2021 | +5.1% | +5.4% | +20.8% | |
| Q1 2021 | -8.4% | -3.9% | -8.0% | |
| Q4 2020 | -4.5% | -36.8% | -40.0% | |
| Q3 2020 | +8.8% | +19.0% | +43.9% | |
| Q2 2020 | +0.0% | -4.2% | -1.2% | |
| Q1 2020 | -2.2% | -0.7% | +4.5% | |
| Q4 2019 | -7.9% | -16.4% | -27.6% | |
| Q3 2019 | -15.1% | -16.8% | -18.8% | |
| Q2 2019 | -0.9% | +4.6% | +13.9% | |
| Q1 2019 | -12.3% | -19.4% | -25.2% | |
| Q4 2018 | +23.8% | +17.2% | +27.8% | |
| Q3 2018 | +0.0% | -1.1% | -2.7% | |
| Q2 2018 | -26.8% | -29.3% | -29.9% | |
| Q1 2018 | +2.3% | +8.7% | +13.3% | |
| Q4 2017 | -10.4% | -13.5% | -30.3% | |
| Q3 2017 | -7.1% | +0.3% | -4.3% | |
| Q2 2017 | -5.7% | -2.5% | +61.5% | |
| Q1 2017 | +13.8% | -5.4% | +39.3% | |
| Q4 2016 | +9.9% | +2.5% | -34.2% | |
| Q3 2016 | +44.9% | +51.2% | +51.2% | |
| Q2 2016 | -6.2% | +2.0% | -27.6% | |
| Q1 2016 | -28.5% | — | — | |
| Q4 2015 | +6.0% | — | — | |
| Q3 2015 | -19.9% | — | — | |
| Q2 2015 | +4.5% | — | — | |
| Q1 2015 | -8.4% | — | — | |
| Q4 2014 | +2.8% | — | — | |
| Q3 2014 | -1.5% | — | — | |
| Q2 2014 | -8.0% | — | — | |
| Q1 2014 | +5.8% | — | — | |
| Q4 2013 | +5.9% | — | — | |
| Q3 2013 | +7.3% | — | — | |
| Q2 2013 | -5.1% | — | — | |
| Q1 2013 | +11.0% | — | — | |
| Q4 2012 | -1.9% | — | — | |
| Q3 2012 | +2.6% | — | — | |
| Q2 2012 | +3.9% | — | — | |
| Q1 2012 | -8.3% | — | — | |
| Q4 2011 | +7.9% | — | — | |
| Q3 2011 | -1.6% | — | — | |
| Q2 2011 | -10.1% | — | — | |
| Q1 2011 | -11.8% | — | — | |
| Q4 2010 | -5.5% | — | — | |
| Q3 2010 | -2.3% | — | — | |
| Q2 2010 | -0.7% | — | — | |
| Q1 2010 | +3.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro